Week 2 Discussion is Psychiatric Evaluation and Evidence Based Rating Scales. reply enelyam b

 

Week 2 Discussion.

The Generalized Anxiety Disorder-7 scale, or GAD-7, is a brief self-report screening tool used to assess anxiety symptoms and monitor symptom severity over time. It includes seven questions focused on symptoms experienced during the past two weeks, with scores ranging from 0 to 21. Higher scores indicate greater anxiety severity, with the tool classifying symptoms as minimal, mild, moderate, or severe.

Three important components of the psychiatric interview are the therapeutic relationship, the history of present illness, and the safety/risk assessment. The therapeutic relationship is essential because psychiatric assessment depends on trust, openness, and the client’s willingness to discuss sensitive information. When clients feel respected and not judged, they are more likely to disclose anxiety symptoms, trauma exposure, substance use, depressive symptoms, or suicidal thoughts. This relationship also allows the provider to observe the client’s affect, behavior, speech, eye contact, and engagement during the interview.

A second important component is the history of present illness. This part of the interview explores the onset, duration, frequency, severity, triggers, associated symptoms, functional impairment, and previous treatment or coping strategies. For a client presenting with anxiety, this information helps the provider determine whether the symptoms are most consistent with generalized anxiety disorder, panic disorder, trauma-related anxiety, substance-induced anxiety, depression with anxious distress, or anxiety related to a medical condition. The GAD-7 can support this process by giving the provider a measurable symptom baseline and a structured way to evaluate anxiety severity (O’Connor et al., 2023).

A third important component is the safety and risk assessment. Even when anxiety is the main concern, the psychiatric interview should include assessment of suicidal ideation, self-harm, homicidal ideation, psychosis, substance use, impulsivity, protective factors, and access to lethal means. This is important because anxiety symptoms may occur with depression, trauma, substance use, and other psychiatric conditions that can increase risk. A complete safety assessment helps the provider determine whether the client can be managed outpatient or needs a higher level of care.

The GAD-7 has strong psychometric support as a screening and symptom-monitoring tool. Recent evidence supports its reliability, validity, and clinical usefulness. Villarreal-Zegarra et al. (2024) found that the GAD-7 demonstrated strong reliability and supported a one-factor structure in a large general population sample. López et al. (2025) also found that the GAD-7 was a valid and reliable instrument for assessing generalized anxiety symptoms across a large Latin American sample, which supports its usefulness across diverse populations. In addition, Park and Park (2025) found that the GAD-7 had acceptable diagnostic accuracy for screening anxiety disorders in their updated systematic review and meta-analysis. O’Connor et al. (2023) also reported that anxiety screening instruments, including the GAD-7, showed adequate accuracy for detecting generalized anxiety disorder in adults.

The GAD-7 is appropriate to use during the psychiatric interview when a client reports excessive worry, nervousness, restlessness, irritability, difficulty relaxing, fearfulness, poor sleep, or physical symptoms that may be anxiety-related. It can be used during the initial psychiatric evaluation to establish a baseline and during follow-up visits to measure response to psychotherapy, medication, or combined treatment. For example, a client beginning cognitive behavioral therapy for anxiety may complete the GAD-7 at intake and again after several sessions to evaluate whether symptoms are improving.

For the psychiatric nurse practitioner, the GAD-7 is helpful because it provides a standardized way to quantify anxiety symptoms, monitor progress, and guide treatment planning. However, it should not be used as the only basis for diagnosis. A high score suggests clinically significant anxiety symptoms, but the provider must still complete a full psychiatric interview, assess functional impairment, consider differential diagnoses, rule out medical or substance-related causes, and evaluate comorbid conditions. When used correctly, the GAD-7 strengthens psychiatric assessment by combining client self-report, evidence-based measurement, and clinical judgment.

References

López, N., Morales-Asencio, B., Ripoll-Córdoba, D., Coronado-López, J., Caldichoury, N., Quispe-Ayala, C., Salazar, D., Florez, Y., Flores-Poma, I., Castellanos, C., Herrera Pino, J., Quispe-Rodríguez, I., Cárdenas-Valverde, J., Alcos-Flores, K., Muñoz-Romero, E., Cantillo-Pacheco, K., Martínez-Sande, P., Camargo, L., Ocampo-Barba, N., ... Gargiulo, P. A. (2025). Internal validity and reliability of the GAD-7 test in Latin America. Chronic Stress, 9. https://doi.org/10.1177/24705470251315260Links to an external site.

O’Connor, E. A., Henninger, M., Perdue, L. A., Coppola, E. L., Thomas, R. G., & Gaynes, B. N. (2023). Anxiety screening: Evidence report and systematic review for the US Preventive Services Task Force. JAMA, 329(24), 2164–2177. https://doi.org/10.1001/jama.2023.6369Links to an external site.

Park, S. H., & Park, S. K. (2025). An updated systematic review and meta-analysis of the predictive validity of the General Anxiety Disorder-7 and General Anxiety Disorder-2 in screening for anxiety disorders. Journal of Affective Disorders, 391, 119913. https://doi.org/10.1016/j.jad.2025.119913Links to an external site.

Villarreal-Zegarra, D., Paredes-Angeles, R., Mayo-Puchoc, N., Arenas-Minaya, E., Huarcaya-Victoria, J., & Copez-Lonzoy, A. (2024). Psychometric properties of the GAD-7: A cross-sectional study of the Peruvian general population. BMC Psychology, 12, Article 183. https://doi.org/10.1186/s40359-024-01688-8Links to an external site.